GSK plc Reports Transaction in Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jul 17, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transaction, 6-K, foreign-issuer
TL;DR
GSK bought back its own shares on 7/17/25. #ShareRepurchase
AI Summary
GSK plc announced a transaction in its own shares on July 17, 2025. The company, formerly known as GlaxoSmithKline PLC, is a pharmaceutical preparations company based in London, UK. This filing is a report of a foreign private issuer.
Why It Matters
This filing indicates GSK is actively managing its share capital, which can impact share price and investor perception.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share transactions and does not present new material risks.
Key Players & Entities
- GSK plc (company) — Registrant
- GlaxoSmithKline PLC (company) — Former company name
- July 2025 (date) — Reporting period
- 79 New Oxford Street, London, WC1A 1DG (location) — Principal executive office
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What is the primary subject of this report?
The report concerns a 'Transaction in own shares' by GSK plc.
When is this report filed as of?
The filing is as of July 17, 2025.
What is GSK plc's principal executive office address?
GSK plc's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Does GSK plc file annual reports under Form 20-F or 40-F?
GSK plc indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 17, 2025 regarding GSK plc (GLAXF).